Estradiol + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvovaginal Atrophy
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
Trial Timeline
Sep 1, 2014 → Oct 1, 2015
NCT ID
NCT02253173About Estradiol + Placebo
Estradiol + Placebo is a phase 3 stage product being developed by TherapeuticsMD for Vulvovaginal Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT02253173. Target conditions include Vulvovaginal Atrophy, Menopause, Dyspareunia.
What happened to similar drugs?
1 of 7 similar drugs in Vulvovaginal Atrophy were approved
Approved (1) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02253173 | Phase 3 | Completed |
| NCT02449902 | Phase 2 | Completed |
Competing Products
10 competing products in Vulvovaginal Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene Vaginal | Novo Nordisk | Phase 3 | 40 |
| Fluconazole | Pfizer | Phase 3 | 40 |
| Clotrimazole vaginal tablet + Fluconazole | Bayer | Approved | 40 |
| SCY-078 + Fluconazole | Scynexis | Phase 2 | 25 |
| Ibrexafungerp | Scynexis | Phase 3 | 30 |
| Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet | Scynexis | Phase 3 | 30 |
| Ibrexafungerp | Scynexis | Phase 1 | 19 |
| Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB) | Matinas Biopharma | Phase 2 | 17 |